Research Grant Program - Fibrolamellar Cancer Foundation
Research Grant Program - Fibrolamellar Cancer Foundation supports researchers studying fibrolamellar carcinoma, funding work on the disease, diagnosis, and treatment to advance therapies and potential cures.
Browse similar grants
Funder: Fibrolamellar Cancer Foundation
Due Dates: November 1, 2026 (November cycle) | March 1, 2027 (March cycle) | July 1, 2027 (July cycle) | By prior agreement (time-sensitive requests)
Funding Amounts: Up to $49,500 for one year (resource/preliminary studies); generally up to $200,000 annually for two years (full studies); no general limit for clinical studies
Summary: Funds research to improve understanding of fibrolamellar carcinoma and advance diagnosis, treatment, and potential cures.
Key Information: Collaboration and open sharing of data and resources are conditions of funding.
Description
The Fibrolamellar Cancer Foundation (FCF) supports innovative research on fibrolamellar carcinoma (FLC), a rare liver cancer. Projects may advance understanding of the disease, its diagnosis or epidemiology, or its treatment. FCF is particularly interested in work with a clear path toward novel therapies or clinical trials and, ultimately, a cure.
FCF seeks to make its funding meaningful for patients by working with researchers to shape proposals, avoiding redundant efforts and not displacing existing funding. Its priorities include early-stage ideas with potential patient benefit, foundational resources and knowledge, and research that brings teams together and shares findings, data, reagents, and models early.
